Vestipitant 28-day Tolerance Study

NCT00992160 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

161

Enrollment

INDUSTRY

Sponsor class

Conditions

Sleep Disorders

Interventions

DRUG: GW597599
DRUG: Placebo

Sponsor

GlaxoSmithKline